Invasion suppressor cystatin E/M (CST6): High-level cell type-specific expression in normal brain and epigenetic silencing in gliomas

Laboratory Investigation

Volumn 88, Issue 9, 2008, Pages 910-925

  Qiu, Jingxin ^a   Ai, Lingbao ^a   Ramachandran, Cheppail ^b   Yao, Bing ^a   Gopalakrishnan, Suhasni ^a   Fields, C Robert ^a   Delmas, Amber L ^a   Dyer, Lisa M ^a   Melnick, Steven J ^b   Yachnis, Anthony T ^a   Schwartz, Philip H ^c   Fine, Howard A ^d   Brown, Kevin D ^a   Robertson, Keith D ^a,e  

^a UNIVERSITY OF FLORIDA   (United States)

^b MIAMI CHILDREN'S HOSPITAL   (United States)

^c CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cell invasion; CST6; Cystatin E M; DNA methylation; Glioma; Neural stem cell

Indexed keywords

CYSTATIN; CYSTATIN E; CYSTATIN M;

ARTICLE; ASTROCYTE; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; BRAIN; BRAIN NEOPLASMS; CYSTATINS; DNA METHYLATION; DNA PRIMERS; EPIGENESIS, GENETIC; GENE SILENCING; GLIOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM INVASIVENESS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 50249153514     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.66     Document Type: Article

References (68)

1. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nature Rev Genet 2002;3:662-673.
2. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692.
3. Chen RZ, Pettersson U, Beard C, et al. DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93.
4. Eden A, Gaudet F, Waghmare A, et al. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003;300:455.
5. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002;3:415-428.
6. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has a non-random and tumor-type-specific patterns. Nature Genet 2000;25:132-138.
7. Bachman KE, Herman JG, Corn PG, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802.
8. Sato N, Maehara N, Su SG, et al. Effects of 5-aza-2′- deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 2003;95:327-330.
9. Akiyama Y, Maesawa C, Ogasawara S, et al. Cell-type specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am J Clin Pathol 2003;163:1911-1919.
10. Kim T-Y, Zhong S, Fields CR, et al. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006;66:7490-7501.
11. Foltz G, Ryu G-Y, Yoon J-G, et al. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma. Cancer Res 2006;66:6665-6674.
12. Coopman PJ, Mueller SC. The syk tyrosine kinase: a new negative regulator in tumor growth and progression. Canc Lett 2006;241:159-173.
13. Ordway JM, Bedell JA, Citek RW, et al. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis 2006;27:2409-2423.
14. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-6369.
15. Laird PW. The power and the promise of DNA methylation markers. Nature Rev Canc 2003;3:253-266.
16. Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004;5:782-792.
17. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93-108.
18. Bellail AC, Hunter SB, Brat DJ, et al. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004;36:1046-1069.
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumors of the Central Nervous System. International Agency for Research on Cancer, 4th edn. IARC Press: Lyon, 2007.
20. Maher EA, Funari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-1333.
21. Baldwin RT, Preston-Martin S. Epidemiology of brain tumors in childhood - a review. Toxicol Appl Pharmacol 2004;199:118-131.
22. Pietsch T, Taylor MD, Rutka JT. Molecular pathogenesis of childhood brain tumors. J Neurooncol 2004;70:203-215.
23. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 2003;144:134-142.
24. Gonzalez-Gomez P, Bello MJ, Lomas J, et al. Epigenetic changes in pilocytic astrocytomas and medulloblastomas. Int J Mol Med 2003;11:655-660.
25. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nature Rev Canc 2003;3:489-501.
26. Levicar N, Strijnik T, Kos J, et al. Lysosomal enzymes, cathepsins in brain tumour invasion. J Neurooncol 2002;58:21-32.
27. Mohanam S, Jasti SL, Kondraganti SR, et al. Down-regulation of cathepsin B expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2001;20:3665-3673.
28. Yanamandra N, Gumidyala KV, Waldron KG, et al. Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 2004;23:2224-2230.
29. Sivaparvathi M, Sawaya R, Wang SW, et al. Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 1995;13:49-56.
30. Sivaparvathi M, Sawaya R, Chintala SK, et al. Expression of cathepsin D during the progression of human gliomas. Neurosci Lett 1996;208:171-174.
31. Abrahamson M, Alvarez-Fernandez M, Nathanson C-M. Cystatins.
32. Biochem Soc Symp 2003;70:179-199.
33. Hong J, Yoshida K, Rosner MR. Characterization of a cysteine proteinase inhibitor induced during neuronal cell differentiation. J Neurochem 2002;81:922-934.
34. Ni J, Abrahamson M, Zhang M, et al. Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins. J Biol Chem 1997;272:10853-10858.
35. Shridhar R, Zhang J, Song J, et al. Cystatin M suppresses the malignant phenotype of human MDA-MD-435S cells. Oncogene 2004;23:2206-2215.
36. Zhang J, Shridhar R, Dai Q, et al. Cystatin M: a novel candidate tumor suppressor gene for breast cancer. Cancer Res 2004;64:6957-6964.
37. Schwartz PH, Bryant PJ, Fuja TJ, et al. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003;74:838-851.
38. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403.
39. Ramachandran C, Khatib Z, Escalon E, et al. Molecular studies in pediatric medulloblastomas. Brain Tumor Pathol 2002;19:15-22.
40. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med 1998;4:844-847.
41. Ai L, Kim W-J, Kim T-Y, et al. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res 2006;66:7899-7909.
42. Widera D, Grimm W-D, Moebius JM, et al. Highly efficient neuronal differentiation of human somatic stem cells, isolated by minimally invasive periodontal surgery. Stem Cells Dev 2007;16:447-460.
43. Keppler D. Towards novel anti-cancer strategies based on cystatin function. Canc Lett 2006;235:159-176.
44. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-1831.
45. Wolswijk G, Noble M. Identification of an adult-specific glial progenitor cell. Development 1989;105:387-400.
46. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
47. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007;2:2265-2275.
48. Sutter R, Yadirgi G, Marino S. Neural stem cells, tumour stem cells, and brain tumours: Dangerous relationships? Biochim Biophys Acta 2007;1776:125-137.
49. Li A, Walling J, Kotliarov Y, et al. Genomic changes and gene expression profiles reveal that established glioma lines are poorly representative of primary human gliomas. Mol Canc Res 2008;6:21-30.
50. Ullrich NJ, Pomeroy SL. Pediatric brain tumors. Neurol Clin 2003;21:897-913.
51. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet 1999;21:103-107.
52. Cheng T, Hitomi K, van Vlijmen-Willems IM, et al. Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J Biol Chem 2006;281:15893-15899.
53. Goulet B, Baruch A, Moon NS, et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell 2004;14:207-219.
54. Hook VY. Unique neuronal functions of cathepsin L and B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease. Biol Chem 2006;384:1429-1439. 54. Rivenbark AG, Jones WD, Coleman WB. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines. Lab Invest 2006;86:1233-1242.
55. Schagdarsurengin U, Pfeifer GP, Dammann R. Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene 2007;26:3089-3094.
56. Zhong S, Fields CR, Su N, et al. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 2007;26:2621-2634.
57. Sivaparvathi M, Mc Cutcheon I, Sawaya R, et al. Expression of cysteine protease inhibitors in human gliomas and meningiomas. Clin Exp Metastasis 1996;14:344-350.
58. Konduri SD, Yanamandra N, Siddique K, et al. Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells. Oncogene 2002;21:8705-8712.
59. Mikkelsen T, Yan PS, Ho KL, et al. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg 1995;83:285-290.
60. Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004;23:4681-4689.
61. Rempel SA, Rosenblum ML, Mikkelsen T, et al. Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 1994;54:6027-6031.
62. Lee J, Son MJ, Woolard K, et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008;13:69-80.
63. Bao S, Wu Q, Mc Lendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
64. Kline NE, Sevier N. Solid tumors in children. J Pediatr Nurs 2003;18:96-102.
65. Song J, Jie C, Polk P, et al. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: Down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. Biochem Biophys Res Commun 2006;340:175-182.
66. Vigneswaran N, Wu J, Nagaraj N, et al. Silencing of cystatin M in metastatic oral cancer line MDA-686Ln by siRNA increases cysteine proteinases and legumain activities, cell proliferation and in vitro invasion. Life Sciences 2006;78:898-907.
67. Taupin P, Ray J, Fischer WH, et al. FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor. Neuron 2000;28:385-397.
68. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16:558-564.